Waters Corporation management check
WAT · Health Care · Life Sciences Tools & Services · CEO Dr. Batra
Filings as of
Closest peers in Life Sciences Tools & Services
- 101WATWaters Corporation76
- 108MTDMettler Toledo76
- 151DHRDanaher Corporation72
- 168IQVIQVIA71
- 307TMOThermo Fisher Scientific61
- 375CRLCharles River Laboratories56
- 386AAgilent Technologies55
- 443ILMNIllumina, Inc.47
- 453TECHBio-Techne45
The seven checks
- GoodBeat its chosen peers
Have owners done well?
What $100 became since fiscal 2021
100100thDetail
$100 invested at the start of fiscal 2021 grew to $154, against $69 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
8964thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.77 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch2.2% of net income
What does the CEO cost owners?
$14.0m pay · $642.6m net income, FY2025
2227thDetail
$14.0m of reported pay in fiscal 2025, against $642.6m of net income.
- n/aNo recent CEO filing
Do they own the stock?
——Light activity: no buys, $1.4m sold in six months.
- WatchShare count growing
Are owners being diluted?
Diluted shares +0.4% a year; flagged above +2%
Stock pay 1.7% of revenue
4527thDetail
Diluted shares changed +0.4% a year over the last three fiscal years. Stock-based pay was 1.7% of revenue in the latest year.
- Good4 leadership filings in 3 years
Is leadership stable?
4 filings under 8-K 5.02 in 3 years
CEO: Dr. Batra
100100thDetail
CEO in the pay table: Dr. Batra. 4 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed April 9, 2026.
Pay tied most to adjusted non-GAAP organic net income growth
Other key measuresAdjusted non-GAAP organic constant currency revenue growthAdjusted non-GAAP organic net income growthRelative total shareholder return
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Dr. Batra | $14.0m | $10.6m | $3.2m | $154 | $69 | $642.6m |
| 2024 | — | $11.1m | $14.6m | $2.5m | $150 | $72 | $637.8m |
| 2023 | — | $8.7m | −$1.1m | $2.3m | $133 | $76 | $642.2m |
| 2022 | — | $9.4m | $10.8m | $2.7m | $138 | $86 | $707.8m |
| 2021 | — | $8.7m | $19.1m | $2.4m | $151 | $127 | $692.8m |
Insiders and the CEO's stakeQuiet
Light activity: no buys, $1.4m sold in six months.
Open-market trades by officers and directors since May 21, 2026.
- SoldChristopher A KueblerDirector$1.4mAug 6, 2026
Leadership and governance on file
All 10 filings
- Aug 21, 2026Leadership change8-K 5.02
- Feb 9, 2026Leadership change8-K 5.02
- Nov 1, 2024Leadership change8-K/A 5.02
- Aug 14, 2024Leadership change8-K 5.02
- Oct 24, 2023Leadership change8-K 5.02
- Mar 28, 2023Leadership change8-K 5.02
- Dec 14, 2022Leadership change8-K/A 5.02
- Nov 23, 2022Leadership change8-K 5.02
- Aug 2, 2022Leadership change8-K 5.02
- Apr 1, 2022Leadership change8-K 5.02
Latest shareholder vote results: May 22, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $1.4bn returned to owners in buybacks and dividends, 41% of net income, and $208.2m of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.8bn | $3.0bn | $3.0bn | $3.0bn | $3.2bn |
| Net income | $692.8m | $707.8m | $642.2m | $637.8m | $642.6m |
| Stock-based pay | $29.9m | $42.6m | $36.9m | $44.7m | $54.1m |
| Buybacks | $648.9m | $626.1m | $70.3m | $13.5m | $14.7m |
| Dividends | — | — | — | — | — |
| Diluted shares | 62m | 60m | 59m | 60m | 60m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.